Advertisement

Biological Dispersion and the Design of Site-Specific Protein Therapeutic Systems

  • E. Tomlinson
Part of the NATO ASI Series book series (NSSA, volume 199)

Abstract

A drug acts when it reaches its pharmacological site of action. However, ideal clinical effectiveness relies additionally on the right amount of drug reaching its site(s) of action at the right rate and frequency, on (often) a drug-free interval (at the receptor site), and on not critically interacting with non-target sites. Few drugs in use today attain such ideality. As more attention is paid to drug/receptor interactions, (often through the use of molecular modelling procedures and/or the use of cloned endogenous proteins which can act as templates for the designed fit of agonist or antagonist drugs), increased effort is being focussed on controlling the biological dispersion of drugs. This activity, which was once reserved almost exclusively for cytotoxic drugs, is an increasingly important aspect of the discovery and drug development process, particularly in the design of therapeutic proteins. Approaches to site-specific delivery include simple low molecular weight prodrugs activated at sites of disease, suicide enzyme substrate inhibitors; polymeric soluble and particulate macromolecular carriers; and unique site-specific therapeutic proteins.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abuchowski, A., Van Es, T., Palczuk, N.C. and Davis, F.F., 1977, Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol, J.Biol.Chem., 252:3578.Google Scholar
  2. Akiyama, A., Bednarski, M., Kim, M-J., Simon, E.S., Waldmann, H. and Whitesides, G.M., 1987, Enzymes in organic synthesis, Chem.Brit., 645.Google Scholar
  3. Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Sharma, S.K., Melton, R.G. and Sherwood, R.F., 1988, A cytotoxic agent can be selectively generated at cancer sites, Br.J.Cancer, 58:700.CrossRefPubMedGoogle Scholar
  4. Berger, E.G., Greber, U.F. and Mosbach, K., 1986, Galactosyltransferase- dependent sialylation of complex and endo-N-acetylglucosaminidase H- treated core N-glycans in vitro, FEBS Lett. 203:64.CrossRefGoogle Scholar
  5. Berger, E.G., Muller, U., Aegerter, E. and Strous, G.J., 1987, Biology of galactosyltransferase: recent developments, Biol.Chem.Trans., 15:610.Google Scholar
  6. Blakey, D.C. and Thorpe, P.E., 1986, Effect of chemical deglycosylation on the in vivo fate of ricin A-chain, Cancer Drug Delivery, 3:189.CrossRefGoogle Scholar
  7. Capon, D.J., Chamow, S.M., Mordenti, J., Marsters, S.A., Gregory, T., Mitsuya, H., Bym, R.A., Lucas, C., Würm, F.M., Groopman, J.E., Broder, S. and Smith, D.H., 1989, Designing CD4 immunoadhesins for AIDS therapy. Native, 337:525.Google Scholar
  8. Caras, I.W., 1989, Nucleic acid and methods for the synthesis of novel fusion polypeptides with a phospholipid anchor, Intnl. Patent Appl., Publ.9.2.89, WO 89/01041.Google Scholar
  9. Chaudhary, V.K., Queen, C., Junghans, R.P. and Walkmann, T.A., Fitzgerald, D.J. and Pastan, I., 1989, A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature, 339:394.CrossRefGoogle Scholar
  10. Chien, S., Fan, F., Lee, M.M.L. and Handley, D.A., 1984, Effects of arterial pressure on endothelial transport of macromolecules, Biorheology, 21:631.CrossRefGoogle Scholar
  11. Collen, D., Stassen, J-M. and Larsen, G., 1988, Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasmingen activator in rabbits, Blood, 71:216.Google Scholar
  12. Cordonnier, A., Montagnier, L. and Emerman, M., 1989, Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature, 340:571.CrossRefGoogle Scholar
  13. Donahue, R.E., Wang, E.A., Kaufman, R.J., Foutch, L., Leary, A.C., Witek- Giannetti, J.S., Metzger, M., Hewick, R.M., Steinbrink, D.R., Shaw, G., Kamen, R. and Clark, S.C., 1986, Effects of N-linked carbohydrate on the in vivo properties of human GM-CSF, Cold Spring Harbor Symposia on Quantitative Biology, Vol. II:685.Google Scholar
  14. Furbish, F.S., Steer, C.J., Krett, N.L. and Barranger, J.A., 1981, Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation, Biochim.Biophys.Acta, 673:425.CrossRefPubMedGoogle Scholar
  15. Harber, E., Quertermous, T., Matsueda, G.R. and Runge, M.S., 1989, Innovative approaches to plasminogen activator therapy, Science, 243:51.CrossRefGoogle Scholar
  16. Jain, R.K., 1987, Transport of molecules across tumor vasculature. Cancer Metastasis Rev, 6:559.CrossRefPubMedGoogle Scholar
  17. Jain, R.K. and Baxter, L.T., 1989, Delivery of novel therapeutic agents in tumors: physiological barriers and strategies, J.Natl.Cancer Inst., 81:570.CrossRefPubMedGoogle Scholar
  18. Jain, R.K. and Baxter, L.T., 1988, Mechanisms of heterogeneous distribution of monoclonal antibodies and other molecules in tumors: significance of elevated interstitial pressure. Cancer Res., 48:7022.Google Scholar
  19. Katre, N.V., Young, J.D. and Zimmerman, R., 1989, Chemical modification of interleukin 2 with polymers: a potent drug-delivery system, in: “Therapeutic Peptides and Proteins”, Current Conmunications in Molecular Biology, Cold Spring Harbor Laboratory.Google Scholar
  20. Katz, D.H., Hamaoka, T., and Benecerraf, B., 1972, Immunological tolerance in bone marrow-derived lymphocytes. I. Evidence for an intracellular mechanism of inactivation of hapten-specific precursors of antibody- forming cells, J.Exp.Med., 136:1410.Google Scholar
  21. Lee, W.Y., Sehon, A.H. and Akerblom, E., 1981, Suppression of reaginic antibodies with modified allergens. IV. Induction of suppressor T cells by conjugates with polyethylene glycol (PEG) and monomethoxy PEG with ovalbumin. Int.Archs.Allergy Appl.Immunol., 64:100.CrossRefGoogle Scholar
  22. Levin, P.A., Patlak, C.C. and Landhal, H.D., 1980, Heuristic modelling of drug delivery to malignant brain tumours, J.Pharmacokinetics Biopharm., 8:257.CrossRefGoogle Scholar
  23. Madison, M.L., Goldsmith, E.J., Gerard, R.D., Gething, M.J.H. and Sambrook, J.F., 1989, Serpin-resistant mutants of human tissue-type plasminogen activator. Nature, 339:721.CrossRefGoogle Scholar
  24. Murakami, T., Kishimoto, M., HLgashi, Y., Amagase, H., Fuwa, T. and Yata, N., 1989, Down-regulation and its effect on epidermal growth factor receptors on the pharmacokinetics of human epidermal growth factor after i.v. administration in rats. Int.J.Pharmaceutics, 54:259.CrossRefGoogle Scholar
  25. Murphy, J.R., 1987, Hybrid Protein, U.S. Patent, 4,675,382, June 23, 1987.Google Scholar
  26. Norde, W., 1984, Physicochemical aspects of the behaviour of biological components at solid liquid interfaces, to: “Microspheres and Drug Therapy. Pharmaceutical, Immunological and Medical Aspects”, S.S. Davis, L. Illm, J.G. McVie and E. Tomlinson, eds., Elsevier, Amsterdam.Google Scholar
  27. Napper, D.H. and Netschey, A., 1971, Studies of the steric stabilisation of colloidal particles, J.Colloid Interface Sci., 37:528.CrossRefGoogle Scholar
  28. Okada, M., Matsushima, A., Katsiihata, A., Aoyama, T., Ando, T. and Inada, Y., 1985, Suppression of IgE antibody response against ovalbumin by the chemical conjugate of ovalbumin with a polyaspartic acid derivative, Int.Archs.Allergy Applied.Immunol., 76:79.CrossRefGoogle Scholar
  29. Ottewill, R.H., 1977, Stability and instability in disperse systems, J.Colloid Interface Sci.,58:357.CrossRefGoogle Scholar
  30. Pearlman, R. and Nguyen, T.H., 1989, Formulation strategies for recombinant proteins: human growth hormone and tissue plasminogen activator, in: “Therapeutic Peptides and Proteins”, Current Communications in Molecular Biology, Cold Spring Harbor Laboratory.Google Scholar
  31. Pohl, G., Hansson, L. and Lowenadler, B., Novel fibrinolytic enzymes, Europ.Patent Appl., 14.06.88, Publ. No. 0 297 Al.Google Scholar
  32. Pincus, S.H., Wehrly, K., Cheseboro, B., 1989, Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates, J.Immunol., 142:3070.Google Scholar
  33. Reiter, Y. and Fishelson, Z.V.I., 1989, Targeting of complement to tumor cells by heteroconjugates comprised of antibodies and of the complement component C3b, J.Immunol., 142:2771.Google Scholar
  34. Rihova, B., Kopecek, J., Kopeckova-Rejmanova, P., Strohalm, J., Plocova, D. and Semoradova, H., 1986, Bioaffinity therapy with antibodies and and drugs bound to soluble synthetic polymers, J.Chromatogr., 376:221.CrossRefGoogle Scholar
  35. Rippe, B. and Stelin, G., 1989, Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism, Kidney Int., 35:1234.CrossRefGoogle Scholar
  36. Scott, C.F., Lambert, J.M., Goldmacher, V.S., Blattler, W.A., Sobel, R., Schlossman, S.F. and Benecerraf, B., 1987, The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies. Int. J.Immunopharmac., 9:211.CrossRefGoogle Scholar
  37. Segawa, A., Borges, M.S., Yokota, Y., Matsushima, A., Inada, Y. and Tada, T., 1981, Suppression of IgE antibody response by the fatty acid- modified antigen. Int.Archs.Allergy Appl. Iryinol., 66:189.CrossRefGoogle Scholar
  38. Taetle, R., Honeysett, J.M. and Houston, L.L., 1988, Effects of anti- epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate of growth of human cells., J.Natl.Cancer Inst., 80:1053.CrossRefPubMedGoogle Scholar
  39. Tomlinson, E., 1986, (Patho)physiology and the temporal and spatial aspects of drug delivery, in: “Site-Specific Drug Delivery”, E. Tomlinson and S.S. Davis, eds., John Wiley & Sons, Chichester.Google Scholar
  40. Tomlinson, E., 1987, Theory and practice of site-specific drug delivery. Advanced Drug Delivery Reviews, 1:87.CrossRefGoogle Scholar
  41. Tomlinson, E., 1989, Considerations in the physiological delivery of therapeutic proteins, in: “Novel Drug Delivery and its Therapeutic Applications”, L.F. Prescott and W.S. Nimmo, eds., John Wiley & Sons Ltd., Chichester.Google Scholar
  42. Tomlinson, E., 1990a, Control of the biological dispersion of therapeutic proteins, in: “Protein Design and the Development of New Therapeutics and Vaccines”, G. Poste and S.T. Crooke, eds. Plenum Press, New York, in press.Google Scholar
  43. Tomlinson, E., 1990b, Selective delivery of protein drugs, to: Protein Production, T.J.R. Harris and C.C.G. Hentschel, eds, in press.Google Scholar
  44. Torchilin, V.P., Khaw, B.A., Klibanov, A.L., Slinkin, M.A., Haber, E. and Smimov, V.N., 1986, Modification of monoclonal antibodies by polymers possessing chelating properties. Bull.Exp.Biol.Med., 102:946.CrossRefGoogle Scholar
  45. Traunecker, A., Schneider, J., Kiefer, H. and Karjalainen, K., 1989, Highly efficient neutralisation of HIV with recombinant CD4-immunoglobulin molecules. Nature, 339:68.CrossRefGoogle Scholar
  46. Vera, D.R., Krohn, K.A., Stadalnik, R.C. and Scheibe, P.O., 1984, Tc-99m- galactosyl-neoglycoalbumin: in vivo characterisation of receptor- mediated binding to hepatocytes. Radiology, 151:191.CrossRefGoogle Scholar
  47. Vitetta, E.S., Fulton, R.J., May, R.D. and Uhr, J.W., 1987, Redesigning nature’s poisons to create anti-tumor reagents. Science, 238:1098.CrossRefGoogle Scholar
  48. White, C.W., Jackson, J.H., Abuchowski, A., Kazo, G.M., Mimmack, R.F., Berger, E.M., Freeman, B.A., McCord, J.M. and Repine, J.E., 1989, Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats, J.Appl.Physiol., 66:584.CrossRefGoogle Scholar
  49. Wileman, T.E., Foster, R.L. and Elliott, P.N.C., 1986, Soluble asparaginase- dextran conjugates show increased circulatory persistence and lowered antigen reactivity, J.Pharm.Pharmacol., 38:264.CrossRefGoogle Scholar
  50. Williams, B.D., O’Sullivan, M.M., Saggu, G.S., Williams, K.E., Williams, L.A. and Morgan, J.R., 1986, Imaging of rheumatoid arthritis using liposomes labelled with technetium, Brit.Med.J., 293:1143.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • E. Tomlinson
    • 1
  1. 1.Advanced Drug Delivery ResearchCiba-Geigy PharmaceuticalsHorsham, West SussexUK

Personalised recommendations